JPS638087B2 - - Google Patents
Info
- Publication number
- JPS638087B2 JPS638087B2 JP17824186A JP17824186A JPS638087B2 JP S638087 B2 JPS638087 B2 JP S638087B2 JP 17824186 A JP17824186 A JP 17824186A JP 17824186 A JP17824186 A JP 17824186A JP S638087 B2 JPS638087 B2 JP S638087B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- patients
- ppn
- years
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 201000011510 cancer Diseases 0.000 claims description 25
- 150000004032 porphyrins Chemical class 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000003449 preventive effect Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 27
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 21
- 229950003776 protoporphyrin Drugs 0.000 description 21
- 230000002354 daily effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 230000012010 growth Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000004324 lymphatic system Anatomy 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000003915 cell function Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- -1 Cobroporphyrin Chemical compound 0.000 description 1
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 description 1
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 description 1
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000011195 Profilin Human genes 0.000 description 1
- 108050001408 Profilin Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000009045 body homeostasis Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003569 hematoporphyrin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17824186A JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17824186A JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51028506A Division JPS6052124B2 (ja) | 1975-03-17 | 1976-03-16 | 悪性腫瘍防止剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62161725A JPS62161725A (ja) | 1987-07-17 |
| JPS638087B2 true JPS638087B2 (https=) | 1988-02-19 |
Family
ID=16045061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17824186A Granted JPS62161725A (ja) | 1986-07-29 | 1986-07-29 | 悪性腫瘍防止剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62161725A (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020241164A1 (ja) | 2019-05-24 | 2020-12-03 | 信越化学工業株式会社 | プラスチック用離型剤 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126953A0 (en) | 1998-11-08 | 1999-09-22 | Yeda Res & Dev | Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives |
| CA2528347A1 (en) * | 2003-06-06 | 2005-01-06 | Eukarion, Inc. | Orally bioavailable low molecular weight metalloporphyrins as antioxidants |
| JP5182858B2 (ja) * | 2007-12-26 | 2013-04-17 | 独立行政法人産業技術総合研究所 | Ｘ線治療用増感剤 |
-
1986
- 1986-07-29 JP JP17824186A patent/JPS62161725A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020241164A1 (ja) | 2019-05-24 | 2020-12-03 | 信越化学工業株式会社 | プラスチック用離型剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62161725A (ja) | 1987-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4393071A (en) | Method of treating gastric, mammary, lung and uterus tumors | |
| Karnofsky et al. | Triethylene melamine in the treatment of neoplastic disease: a compound with nitrogen-mustard-like activity suitable for oral and intravenous use | |
| RU2162327C2 (ru) | Лечение рака и профилактика метастазирования | |
| Mackey et al. | Diffuse cutaneous mastocytosis: treatment with oral psoralen plus UV-A | |
| US5006551A (en) | Composition for destroying malignant tumors | |
| Sartori | Cesium therapy in cancer patients | |
| Condon et al. | Treatment of Paget's disease of bone with mithramycin | |
| US8664268B2 (en) | Gallium compositions for the treatment of liver cancer and methods of use | |
| Arnott | The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma | |
| EP2026657A1 (en) | Anti-cancer composition and method for using the same | |
| Campbell et al. | Acute reactions to mega ascorbic acid therapy in malignant disease | |
| JPS638087B2 (https=) | ||
| CN108125940B (zh) | 戊酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途 | |
| Stuart et al. | Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group | |
| Elzawawy | Treatment of 5-fluorouracil-induced stomatitis by allopurinol mouthwashes | |
| JPS6052124B2 (ja) | 悪性腫瘍防止剤 | |
| RU2369396C2 (ru) | Фармацевтическая композиция, содержащая оксоплатин, его соли и производные | |
| US20080038376A1 (en) | Anti-cancer composition and method for using the same | |
| Chanes et al. | Combined actinomycin D and vincristine in the treatment of patients with cancer | |
| CN110227083A (zh) | 一种含氯化钆和双胍类降糖药的药物组合物及其用途 | |
| O'Connell et al. | Phase II clinical trial of triazinate in combination with mitomycin C for patients with advanced gastric cancer. | |
| Yanai et al. | Development of a testicular haemangioma after interferon therapy for hepatic haemangiomas: a case report | |
| JP6937065B1 (ja) | 間質性肺炎の治療剤 | |
| US20100029590A1 (en) | Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt | |
| Folman | Experience with mitomycin in the treatment of non-small cell lung cancer |